# NCT04206072 (NCT04206072)

> D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04206072
- Phase: PHASE2, PHASE3
- Status: COMPLETED
- Sponsor: Betta Pharmaceuticals Co., Ltd.
- Conditions: Non-Small Cell Lung Cancer; EGFR Gene Mutation
- Interventions: D-0316 Capsule; Icotinib Hydrochloride Tablets
- Enrollment: 362
- Primary outcome: Median Progression Free Survival (PFS) assessed by IRC

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04206072